Choline Me

Choline Metabolites and 15-Year Risk of Incident Diabetes in a Prospective Cohort of Adults: Coronary Artery Risk Development in Young Adults (CARDIA)...

OBJECTIVE The potential for choline metabolism to influence the development of diabetes has received increased attention. Previous studies on circulating choline metabolites and incident diabetes have been conducted in samples of older adults, often with a high prevalence of risk factors. RESEARCH DESIGN AND METHODS Participants were from year 15 of follow-up (2000-2001) in the Coronary Artery Risk Development in Young Adults (CARDIA) Study (n = 3,133, aged 33-45 years) with plasma choline metabolite (choline, betaine, and trimethylamine N-oxide [TMAO]) data. We quantified association

Young Electronic Cigarette Users Show Similar Respiratory Function as Tobacco Smokers

Electric cigarette smoking or vaping was associated with impaired resting vascular function, reduced ventilatory efficiency, and amplified exertional dyspnoea that was similar to tobacco smoking, according to a study presented at the 2024 Annual Meet...

Pregnancy-Related Heart Failure Is Underdetected, But AI-Enabled Stethoscope Can Help

In pregnant and postpartum women, artificial intelligence (AI)-guided screening using a digital stethoscope improved the diagnosis of pregnancy-related cardiomyopathy, according to a study published in Nature Medicine. The study, which was also pr...


Sixty Seconds Science


Spotify episodes

Apple podcasts

Google podcasts

Partner

Search:
Date
Filters:
Pre-diabet
6:54

Pre-diabetes: a risk factor for cardiovascular disease? - report from ESC2024

Presenter: Antonio Ceriello
Cardiology
ESC 2024
What is th
4:31

What is the benefit of starting earlier PCSK9 inhibitors for acute coronary syndromes? - report from ESC2024

Presenter: Marc P. Bonaca
Cardiology
ESC 2024
State-of-t
11:37

State-of-the-art molecular diagnostics in lung cancer for the pulmonologist

Presenter: Joanna Chorostowska-Wynimko
Respiratory
ERS 2024
Smoke-free
12:35

Smoke-free Europe: utopia or feasible reality?

Presenter: Nick Hopkinson
Respiratory
ERS 2024
Paediatric
4:35

Paediatric asthma in 2024: from prevention to transition

Presenter: Angela Zacharasiewicz
Respiratory
ERS 2024
How to cha
2:52

How to change urban areas to improve the life of allergic patients?

Presenter: Alessandro Marcon
Respiratory
ERS 2024
COPD in a
10:03

COPD in a nutshell at ERS2024

Presenter: Nick Hopkinson
Respiratory
ERS 2024
Paediatric
3:12

Paediatric asthma in 2024: from prevention to transition

Presenter: Andrew Bush
Respiratory
ERS 2024
2024 ESC G
11:44

2024 ESC Guidelines for the Management of Chronic Coronary Syndromes

Presenter: Christiaan Vrints
Cardiology
ESC 2024
2024 ESC G
8:08

2024 ESC Guidelines for the Management of Atrial Fibrillation

Presenter: Isabelle C. Van Gelder
Cardiology
ESC 2024
Cardiovasc...
2:56

Cardiovascular multimorbid patients’ care

Presenter: Claudio Borghi
Cardiology
ESC 2024
Guidelines
9:23

Guidelines in Practice: implementing the 2023 Focused Update on Heart Failure - target, treat, and titrate

Presenter: Piotr Ponikowski
Cardiology
ESC 2024
Patient en
6:30

Patient engagement in lipid-lowering therapies

Presenter: Vera Bittner
Cardiology
ESC 2024
Chronic is
6:26

Chronic ischaemic syndrome management in 2024: are we ready for the (r)evolution?

Presenter: Mario Marzilli
Cardiology
ESC 2024
FINE-HEART
8:47

FINE-HEART - Participant-level pooled analysis of finerenone in heart failure and chronic kidney disease trials

Presenter: Muthiah Vaduganathan
Cardiology
ESC 2024
EPIC-CAD -
5:02

EPIC-CAD - Edoxaban monotherapy vs. dual antithrombotic therapy for atrial fibrillation and stable coronary artery disease - report from ESC2024

Presenter: Gi-Byoung Nam
Cardiology
ESC 2024
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
The import
11:22

The importance of the anterior interface in eye surgery

Presenter: Marie-José Tassignon
Internal Medicine
Haematolog
17:26

Haematology is at the forefront - interview with EHA President

Presenter: Antonio Almeida
Oncology
Overall Su
13:30

Overall Survival Results of KEYNOTE-564

Presenter: Stefan N. Symeonides
Oncology
General as
1:18

General aspects of the ESH2023 Hypertension Guidelines - What are the major changes?

Presenter: Michel Burnier
Cardiology
How shall
1:23

How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment?

Presenter: Konstantinos Tsioufis
Cardiology
How to tre
1:06

How to treat patients optimally with chronic coronary syndromes in 2023?

Presenter: Luis Henrique Gowdak
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
Oncology
How novel
1:07

How novel AI model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia?

Presenter: Andrew Srisuwananukorn
Hematology
The future
1:10

The future of Multiple Myeloma management

Presenter: Xavier Leleu
Hematology
Benefits o
1:01

Benefits of myeloma regimens in the real world fall well short of trials

Presenter: Alissa Visram
Hematology
The prefer
0:57

The preferred treatment of hypertension with RAAS blockade inhibitors

Presenter: Martin Strauss
Cardiology
What clini
1:16

What clinicians should know about the new ESH guideline regarding hypertension in women?

Presenter: Renata Cifkova
Cardiology
How to man
1:00

How to manage isolated systolic hypertension in the young?

Presenter: Paolo Palatini
Cardiology
Blood pres
1:34

Blood pressure monitoring in general and what we can do to encourage people.

Presenter: Neil Poulter
Cardiology
How to man
1:08

How to manage masked and masked uncontrolled hypertension?

Presenter: Paolo Palatini
Cardiology
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Oncology